FOLFOX-6方案治疗晚期胃肠道肿瘤的临床观察

Clinical study of advanced or metastatic gastric and colorectal cancer patients treated with oxaliplatin combined with 5-fluorouracil and calcium folinate chemotherapy

为了观察FOLFOX-6方案治疗晚期胃肠道肿瘤的近期疗效及毒副反应,对36例晚期胃肠道肿瘤患者予以FOLFOX-6方案化疗,草酸铂(L-OHP)100mg/m2+5%葡萄糖500mL,静脉滴入,3h,d1;亚叶酸钙(CF)200mg/m2+生理盐水250mL,静脉滴入,2h,d1;5-氟尿嘧啶(5-FU)500mg+生理盐水20mL,静脉推注,d1,续以5-FU2500mg/m2微量注射泵持续静脉滴入,46h,d1,d2,每2周重复。2个周期后评价疗效和毒副反应。全组有30例可评价疗效,其中完全缓解(CR)2例,部分缓解(PR)12例,稳定(SD)13例,进展(PD)3例,总有效率(CR+PR)46.7%。化疗后白细胞降低发生率达50.8%,恶心呕吐发生率62.5%,腹泻44.2%,周围神经毒性发生率为35.8%。初步研究结果提示,FOLFOX-6方案治疗晚期胃肠道恶性肿瘤的近期疗效较好,毒副反应可以耐受,值得临床进一步研究应用。

The objective of this study was to evaluate the efficacy and adverse effects of oxaliplatin combined with 5-FU and calcium folinate in the treatment of patients with advanced or metastatic gastric and colorectal cancer. Thirty-six patients with advanced or metastatic gastric and colorectal cancer received chemotherapy of regimen L-OHP 100 mg/m^2,3 hours,d1, CF 200 mg/m^2,2 hours,d1, d2, followed by 5-FU 500 mg/m^2 iv and 2 500 mg/m^2,46 hours,civ,d1 , d2, two weeks as one cycle. The efficacy was evaluated after 2 cycles. Two patients achieved complete response （CR）, 12 patients partial response （PR）, 13 patients stable disease （SD）, 3 patients progression disease （PD）. The overall response rate was 46.7%. The major toxicity included nausea, vomiting, leucopenia and neurosensory. This study shows that the regimen of FOLFOX-6 is effective and tolerable in the treatment of advanced or metastatic gastric and colorectal cancer.